A step back in time: Is there a place for older drugs in the treatment of dementia?

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 59, Issue 10, 2004, Pages 1025-1028

  Belgeri, Myra ^a,b   Morley, John E ^a,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; CYCLIC AMP; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; DOPAMINE; GALANTAMINE; GINKGO BILOBA EXTRACT; LEVACECARNINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICERGOLINE; NOOTROPIC AGENT; PAPAVERINE; PIRACETAM; PLACEBO; RIVASTIGMINE; SEROTONIN; TACRINE; VINPOCETINE;

AGGRESSION; AGING; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DAILY LIFE ACTIVITY; DEMENTIA; DISORIENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; EDITORIAL; HUMAN; LIVER TOXICITY; MEMORY DISORDER; MENTAL DETERIORATION; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RATING SCALE; SHORT TERM MEMORY;

GINKGO BILOBA;

EID: 7444229143     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/59.10.m1025     Document Type: Editorial

References (59)

1. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol Med Sci. 2003;58A:331-353.
2. Morley JE. The top 10 hot topics in aging. J Gerontol Med Sci. 2004;59A:24-33.
3. Banks WA, Morley JE. Memories are made of this: recent advances in understanding cognitive impairments and dementia. J Gerontol Med Sci. 2003;58A:314-321.
4. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol Med Sci. 2004;59A:255-263.
5. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol Biol Sci Med Sci. 2004;59A:268-274.
6. Morley JE, Perry HM, Miller Dk. Something about frailty. J Gerontol Med Sci. 2002;57A:M698-M704.
7. Raji MA, Ostir GV, Markides KS, Goodwin JS. The interaction of cognitive and emotional status on subsequent physical functioning in older Mexican Americans: findings from the Hispanic established population for the epidemiologic study of the elderly. J Gerontol Med Sci. 2002;57A:M678-M682.
8. Morley JE. A fall is a major event in the life of an older person. J Gerontol Med Sci. 2002;57A:M492-M495.
9. Blawn CS, Ofstedal MB, Liang J. Low cognitive performance, comorbid disease, and task-specific disability: findings from a nationally representative survey. J Gerontol Med Sci. 2002;57A:M523-M531.
10. Bortz WM. A conceptual framework of frailty: a review. J Gerontol Med Sci. 2002;57A:M283-M288.
11. Blazer DG, Fillenbaum G, Burchett B. The APOE-E4 allele and the risk of functional decline in a community sample of African American and white older adults. J Gerontol Med Sci. 2001;56A:M785-M789.
12. Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol Med Sci. 2002;57A:M173-M177.
13. Lipsitz LA. Dynamics of stability: the physiologic basis of functional health and frailty. J Gerontol Biol Sci. 2002;57A:B115-B125.
14. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol Med Sci. 2001;56A:M146-M156.
15. Flood JF, Roberts E, Sherman MA, Kaplan BE, Morley JE. Topography of a binding site for small amnestic peptides deduced from structure activity studies - relation to amnestic effect of amyloid beta-protein. Proc Natl Acad Sci U S A. 1994;91:380-384.
16. Flood JF, Morley JE, Roberts E. An amyloid beta-protein fragment, A beta[12-28], equipotently impairs post-training memory processing when injected into different limbic system structures. Brain Res. 1994;663:271-276.
17. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627-638.
18. Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alz Dis Assoc Disord. 2003;17:259-266.
19. Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neurosci. 2003;121:487-492.
20. Phinney AL, Horne P, Yang J, Janus C, Bergeron C, Westaway D. Mouse models of Alzheimer's disease: the long and filamentous road. Neurol Res. 2003;25:590-600.
21. Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE. Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. Life Sci. 2003;73:555-562.
22. Morley JE, Farr SA, Flood JF. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem. 2002;78:125-138.
23. Morley JE, Kumar VB, Bernardo AE, et al. Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides. 2000;21:1761-1767.
24. Kumar VB, Farr SA, Flood JF, et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000;21:1769-1775.
25. Flood JF, Morley JE. Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev. 1998;22:1-20.
26. Blass JP. Cerebrometabolic abnormalities in Alzheimer's disease. Neurol Res. 2003;25:556-566.
27. Aliev G, Seyidova D, Lamb BT, et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease-like pathology in transgenic mice. Neurol Res. 2003;25:665-674.
28. Cash AD, Perry G, Smith MA. Therapeutic potential in Alzheimer disease. Curr Med Chem. 2002;9:1605-1610.
29. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol Med Sci. 2004;59A:478-495.
30. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173-1183.
31. Rockwood K, Wallack M, Tallis R. The treatment of Alzheimer's disease: success short of cure. Lancet Neurol. 2003;2:630-633.
32. Flood JF, Farr SA, Uezu K, Morley JE. Age-related changes in septal serotonergic, GABAergic and glutamatergic facilitation of retention in SAMP8 mice. Mech Ageing Dev. 1998;105:173-188.
33. Flood JF, Morley JE, Lanthom TH. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol. 1992;221:249-254.
34. Reisberg B, Doody R, Sloffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
35. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil - a randomized controlled trial. JAMA. 2004;291:317-324.
36. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-44.
37. Reichman WE. Alzheimer's disease: clinical treatment options. Am J Manag Care. 2000;6(22 Suppl):S1125-S1132; discussion S1133-S1138.
38. Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Datab Systematic Rev. 2004;2.
39. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care. 2000;6(22 Suppl):S1139-S1144; discussion S1145-S1148.
40. Burian E. An ergot alkaloid preparation (hydergine) in the treatment of presenile brain atrophy (Alzheimer's disease): case report. J Am Geriatr Soc. 1974;22:126-128.
41. Yesavage JA, Hollister LE, Burian E. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report. J Am Geriatr Soc. 1979;27:80-82.
42. Theinhaus OJ, Wheeler BG, Simon S, et al. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc. 1987;35:219-223.
43. Rosen HJ. Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine). J Am Geriatr Soc. 1975;23:169-174.
44. van Loveran-Huyben CM, Engelaar HF, Hermans MB, et al. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc. 1984;32:584-588.
45. Thompson TL, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med. 1990;323:445-448.
46. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Datab System Rev. 2004;2.
47. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Dementia and Cognitive Improvement Group. Cochrane Datab System Rev. 2004;2.
48. Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Datab System Rev. 2004;2.
49. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Datab System Rev. 2004;2.
50. Birks J, Grimley Evans J. Ginkgo Biloba for cognitive impairment and dementia. Cochrane Datab System Rev. 2004;2.
51. Andrieu S, Gillette S, Amouyal K, et al. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol Med Sci. 2003;58A:372-377.
52. Hudson S, Tabet N. Acetyl-1-carnitine for dementia. Cochrane Datab System Rev. 2004;2.
53. Tabet N, Birks J, Grimley Evans J, Orrel M, Spector A. Vitamin E for Alzheimer's disease. Cochrane Datab System Rev. 2004;2.
54. Morley JE, Farr SA, Kumar VB, Banks WA. Alzheimer's disease through the eye of a mouse - acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides. 2002;23:589-599.
55. Sauer J, Tabet N, Howard R. Alpha lipoic acid for dementia. Cochrane Datab System Rev. 2004;2.
56. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Datab System Rev. 2004;2.
57. Olin J, Schneider L. Galantamine for dementia due to Alzheimer's disease. Cochrane Datab System Rev. 2004;2.
58. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Datab System Rev. 2004;2.
59. Areosa Sastre A, Sherriff F. Memantine for dementia. Cochrane Datab System Rev. 2004;2.